CVGD - ETF AI Analysis
Top Page
CresAlta Global Dividend ETF (CVGD)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Dividend-Focused Leaders
Several major holdings like CVS Health, Verizon, Elevance Health, and PPG Industries have shown strong year-to-date performance, supporting the fund’s dividend and total return profile.
Broad Sector Diversification
The ETF spreads its investments across many sectors, with meaningful exposure to health care, financials, consumer defensive, and communication services, helping reduce reliance on any single industry.
Moderate Expense Ratio
The fund’s expense ratio is moderate for an actively managed dividend strategy, so fees are not excessively high relative to its specialized focus.
Negative Factors
Heavy U.S. Concentration
With the vast majority of its assets in U.S. companies, the ETF is highly sensitive to the U.S. market and offers limited geographic diversification.
Mixed Performance Among Top Holdings
Some key positions such as Huntington Bancshares, AstraZeneca, Salesforce, and Prudential have shown weak or lagging year-to-date performance, which can drag on overall returns.
Recent Performance Only Slightly Positive
The fund’s year-to-date performance has been only slightly positive and its one-month performance has been slightly negative, suggesting limited recent momentum.
CVGD vs. SPDR S&P 500 ETF (SPY)
AUM134.54M
RegionGlobal
Expense Ratio0.50%
Beta-0.45
IssuerCresAlta
Inception DateMay 18, 2026
Dividend Yield0.28%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,414
30 Day Avg. Volume1,118
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
28.70Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CVGD Summary
CresAlta Global Dividend ETF (CVGD) is an actively managed fund that focuses on companies with steady and growing dividend payments, mainly in the U.S. It invests across many sectors, including health care, financials, and consumer defensive stocks. Well-known holdings include CVS Health and Verizon. Someone might invest in CVGD to seek a mix of regular income and long-term growth, while getting broad diversification across different industries. A key risk is that stock prices and dividend payments can still go up and down with the overall market, so returns are not guaranteed.
How much will it cost me?This ETF has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because CVGD is actively managed, with professionals selecting and monitoring dividend-focused stocks around the world.
What would affect this ETF?This global dividend ETF could benefit if healthcare, financial, and defensive consumer companies remain stable and grow their profits, supporting steady or rising dividends across U.S. and international markets, especially from major holdings like CVS Health, Verizon, and Elevance Health. On the other hand, higher interest rates, economic slowdowns, or regulatory changes in healthcare and financials could pressure company earnings and dividend growth, while its active management approach may underperform if stock selection or sector bets do not work as expected.
CVGD Top 10 Holdings
CVGD leans heavily on health care and financial names, with CVS Health and Elevance Health acting as key engines of recent gains as their shares have been steadily rising. PPG Industries adds a bit of cyclical punch, also trending higher and helping performance. On the other side of the ledger, Salesforce has been losing steam, while AstraZeneca and Prudential are lagging, creating a drag that offsets some of the fund’s strength. With holdings spread across U.S. and international markets, CVGD offers global dividend exposure without betting everything on one country or sector.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ― | 6.81% | $9.04M | ― | ― | ― | |
| CVS Health | 4.31% | $5.73M | $125.45B | 51.62% | 64 Neutral | |
| Verizon | 3.96% | $5.26M | $189.45B | 7.08% | 81 Outperform | |
| Elevance Health | 3.90% | $5.18M | $84.37B | 6.01% | 76 Outperform | |
| Huntington Bancshares | 3.54% | $4.71M | $34.18B | 6.10% | 80 Outperform | |
| Gilead Sciences | 3.23% | $4.28M | $153.66B | 17.59% | 78 Outperform | |
| AstraZeneca | 2.69% | $3.57M | $271.40B | 27.54% | 80 Outperform | |
| Salesforce | 2.61% | $3.47M | $124.31B | -43.01% | 80 Outperform | |
| PPG Industries | 2.45% | $3.25M | $26.36B | 5.87% | 67 Neutral | |
| Prudential | 2.39% | $3.18M | $33.25B | 10.92% | 73 Outperform |
CVGD Technical Analysis
Negative
―
Price Trends
Market Momentum
-0.10
Positive
47.78
Neutral
45.66
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CVGD, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 25.04, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 47.78 is Neutral, neither overbought nor oversold. The STOCH value of 45.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVGD.
CVGD Peer Comparison
Comparison Results
Performance Comparison
CVGD
CresAlta Global Dividend ETF
24.91
-0.09
-0.36%
RGEF
Rockefeller Global Equity ETF
―
―
―
BFLX
iShares Flexible Equity Active ETF
―
―
―
KAT
Scharf ETF
―
―
―
DWLD
Davis Select Worldwide Etf
―
―
―
RGLO
Global Equity Active ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents